NuMed's Prizvalve®: China's First Domestically Developed Balloon-Expandable Transcatheter Aortic Valve System – Launch Event at Artery New Product Showcase Episode 105
NewMed
Artificial Heart Valve System Developer
Highlight Poster
“Prizvalve®Transcatheter Aortic Valve SystemIs byShanghai NewMed Medical Co., Ltd.(hereinafter referred to as "NewMed")Independently DevelopedChina's First Self-Developed Balloon-Expandable Valve, approved for marketing on August 14, 2024. Suitable for patients with symptomatic, calcified, severe degenerative native aortic valve stenosis who are considered unsuitable for conventional surgical valve replacement after assessment by the cardiac team using a scoring system.
This product fills the technical gap in the Chinese market for domestically produced balloon-expandable valves, providing a broader range of treatment options for numerous patients with aortic valve diseases and ushering in the era of balloon-expandable valves for interventional treatment of valvular diseases.
At the 2023 Chengdu International Heart Valve Disease Interventional Treatment Conference, Prizvalve was announced.®One-Year Clinical Follow-Up Data of the Transcatheter Aortic Valve System. In the 120 patients enrolled in the clinical trial, the average age was 74.7 years. The one-year postoperative clinical follow-up results showed an all-cause mortality rate of 2.5%.
On October 28 (Monday) at 19:30, the 105th episode of VCBeat's "New Product Review," invited Yu Qifeng, founder, chairman, and CEO of NewMed, Gao Xinyi, Chief Marketing Officer of NewMed, and Bai Baohong, Business Director of NewMed.“China's First Self-Developed Balloon-Expandable Valve to Hit the Market —— Prizvalve®Transcatheter Aortic Valve SystemProduct Promotion and Sharing.
Prizvalve®Transcatheter Aortic Valve System
Prizvalve®Transcatheter Aortic Valve SystemAsThe First Balloon-Expandable Transcatheter Aortic Valve Product Made in China to Enter Registered Clinical Trials in the Country，对标国际最新一代的球扩瓣技术, in order to make the product more compliant withPathology and Physiological Anatomy of Chinese Patients, adopting a balloon-expandable short stent valve design, with innovations in the valve frame, valve skirt, delivery system, and other aspects.
Product valve frame adoptsCobalt Chromium Alloy, the radial support force it generates can compress the residual valve to a smaller size; uniqueBiological Tissue Processing TechnologyCan further improve the service life of the valve;Internal and External Sealing Membrane Flap Skirt DesignCan effectively reduce paravalvular leakage; the delivery system has superiorBending Performance, making the aortic arch more passable during surgery, effectively reducing damage to the vascular wall and achievingPrecision Positioning。
Due to the design advantages of balloon-expandable valves, there have been numerous international reports on their clinical application in all four heart valves. To date, NewMed's balloon-expandable valve, Prizvalve,®Has assisted Chinese clinical experts in the full "heart" application for all four heart valves., and has also achieved the clinical application adaptation of various devices (surgical valves, interventional valves, annuloplasty rings, stents).Provides a domestically produced solution for China to keep pace with international standards in the treatment of valvular diseases.。
Scan the QR code on the poster to add the assistant and schedule a live broadcast.
Yu Qifeng
Founder, Chairman and CEO of NewMed
Member of the China Zhi Gong Party, with a doctoral degree, senior engineer, and a leading talent in technological entrepreneurship under the national "Ten Thousand Talents Program." Founded NewMed in 2015 and currently serves as the company's Chairman and Chief Executive Officer. Also serves as a director and one of the first senior members of the Chinese Society for Biomaterials (CSBM), a member of the CSBM Medical Metal Materials Branch, a member of the CSBM Biomedical Materials Surface & Interface Engineering Branch, a standing committee member of the Product Reliability Committee of the China Association for Medical Devices Industry, an editorial board member of Congenital Heart Disease (CHD), and a member of the Pudong New Area Political Consultative Conference.
High-Tech Instrument
Chief Marketing Officer of NewMed
15+ Years of Marketing Experience
Bachelor of Preventive Medicine, Peking University
Master of Economic Law, China University of Political Science and Law
Successively served as Regional Sales Vice President, National Director of Imaging Diagnosis Solutions, and National Promotion Director in large medical device groups such as Lepu Medical and MicroPort. Possesses extensive experience in market expansion, sales operations, team building, and management across various interventional fields including cardiovascular, electrophysiology, structural heart disease, as well as in the development of integrated interventional solutions.
Bai Baohong
NewMed Business Director
Majoring in Clinical Medicine, with over 20 years of experience in marketing, commercial operations, and management within the cardiovascular medical device industry. Previously held positions at leading Chinese publicly-listed cardiovascular medical device companies such as Qinming Medical, Lepu Medical, and Xintai Medical, responsible for sales, marketing, operations, and business-related management tasks.
About NewMed
Shanghai NewMed Medical Co., Ltd. was founded in 2015. It is a high-tech medical innovation enterprise with independent intellectual property rights, focusing on the research and development and industrialization of interventional artificial heart valve systems at an internationally advanced level. We are committed to innovative technology research and development, academic promotion, and treatment popularization. We have built a management team that combines production, academia, research, and medicine, and have established good cooperative relationships with well-known hospitals and universities in China.
NewMed's product line covers the aortic valve, mitral valve, tricuspid valve, and pulmonary valve, providing comprehensive innovative solutions for leading valve interventional treatments in China. Three of its R&D products have been recognized by the National Medical Products Administration as innovative medical devices eligible for special review, with multiple core major products currently undergoing clinical trials. The company has applied for over 200 patents and has been awarded the status of a high-tech enterprise at both the national and Shanghai levels. It ranked third in the enterprise group of the biopharmaceutical industry in the 5th China Innovation and Entrepreneurship Competition, was named a star technology innovation enterprise in the 30-year celebration of Shanghai Technology Business Incubators, and has undertaken key research projects under the "13th Five-Year Plan" national program, as well as several projects from the Shanghai Science and Technology Commission and the Pudong New Area.
About VCBeat New Product Review
"VCBeat New Product Review" is a live broadcast column that supports the release of innovative products by medical companies. The aim of the column is to assist in the milestone release of every medical innovation product. If a company has plans to release an innovative medical product or a significant milestone and wishes to participate in the VCBeat New Product Review, please contact the assistant for consultation.
Method 1: Watch the live broadcast via Mini Program
Scan the QR code below to contact the assistant and schedule a live broadcast (if already added, please ask the assistant directly).
Method 2: Watch the live broadcast on the VCBeat app, and win lucky prizes!
Scan the QR code below to download the VCBeat app and register to watch the live stream.
Contact the assistant to send a live broadcast screenshot, and participate in the lucky draw for a chance to win [15-day trial membership of VCBeat's VBInsight].
